{"id":"W2997720498","doi":"10.1001/jamaoncol.2019.5570","title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Genentech; Merck Canada; Deutschen Konsortium für Translationale Krebsforschung; Radboud Universitair Medisch Centrum; Melanoma Institute Australia; Amgen; Radboud Universiteit; Universitat de Barcelona; Astellas Pharma; Les Laboratories Pierre Fabre; European Organisation for Research and Treatment of Cancer; SkylineDx; Sun Pharma; Peter MacCallum Cancer Centre; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Endocyte; Array BioPharma; Aix-Marseille Université; InflaRx; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; GlaxoSmithKline; NeraCare; University of Sydney; Medizinischen Hochschule Hannover; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Placebo; Randomized controlled trial; Clinical trial; Melanoma; Oncology; Surgery; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000988694,0.0002362747,0.001088928,0.000105792,0.00009885826,0.00001087672,0.0001401814,0.0003587804,0.0004197507],"category_scores_gemma":[0.001486884,0.0001679179,0.0001434409,0.0003713865,0.0001148533,0.0001436031,0.0001037082,0.0003765213,0.00002297933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006229864,"about_ca_system_score_gemma":0.0002981707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004167222,"about_ca_topic_score_gemma":0.0002569681,"domain_scores_codex":[0.997578,0.0006024794,0.0006755108,0.0003982319,0.0004016485,0.0003441372],"domain_scores_gemma":[0.9978319,0.0009342015,0.000546696,0.0002357995,0.0002083255,0.0002430905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5861143,0.0001211869,0.3975838,0.00004328692,0.001539861,0.0000364495,0.00260067,0.000003156258,0.00006455532,0.000004970158,0.001819553,0.01006817],"study_design_scores_gemma":[0.4363849,0.003145244,0.5519953,0.0001106264,0.000448348,0.000002654764,0.0003067271,0.00004619257,0.00007230412,0.00001051617,0.007286671,0.0001904689],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882669,0.00008076887,0.00006082262,0.006333456,0.0003636943,0.002285753,0.0001162783,0.00006559325,0.002426701],"genre_scores_gemma":[0.9958522,0.0001457948,0.0002542732,0.0008584603,0.0001402682,0.0001203142,0.0001996247,0.00003229064,0.002396831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1544115,"threshold_uncertainty_score":0.6847493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01442860837970582,"score_gpt":0.2701461534137153,"score_spread":0.2557175450340095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}